Regentis Biomaterials Ltd. (RGNT) - Total Liabilities
Based on the latest financial reports, Regentis Biomaterials Ltd. (RGNT) has total liabilities worth $2.87 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Regentis Biomaterials Ltd. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Regentis Biomaterials Ltd. - Total Liabilities Trend (2022–2025)
This chart illustrates how Regentis Biomaterials Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See Regentis Biomaterials Ltd. (RGNT) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Regentis Biomaterials Ltd. Competitors by Total Liabilities
The table below lists competitors of Regentis Biomaterials Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dare Bioscience Inc
NASDAQ:DARE
|
USA | $29.63 Million |
|
Dycasa SA
BA:DYCA
|
Argentina | AR$23.74 Billion |
|
FingerMotion Inc
NASDAQ:FNGR
|
USA | $48.57 Million |
|
Indonesian Tobacco Tbk PT
JK:ITIC
|
Indonesia | Rp184.04 Billion |
|
Kiora Pharmaceuticals Inc
NASDAQ:KPRX
|
USA | $6.92 Million |
|
Sirona Biochem Corp
V:SBM
|
Canada | CA$4.27 Million |
|
InnSuites Hospitality Trust
NYSE MKT:IHT
|
USA | $14.04 Million |
|
Tier One Silver Inc
V:TSLV
|
Canada | CA$2.03 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Regentis Biomaterials Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RGNT total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regentis Biomaterials Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regentis Biomaterials Ltd. (2022–2025)
The table below shows the annual total liabilities of Regentis Biomaterials Ltd. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.87 Million | -93.09% |
| 2024-12-31 | $41.59 Million | -10.11% |
| 2023-12-31 | $46.27 Million | +5.68% |
| 2022-12-31 | $43.78 Million | -- |
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical tr… Read more